Immunogenicity as a predictive tool for the response to therapy of high mutation load tumors (IMPRESS)

Project: PN-III-P4-ID-PCE-2016-0870



The aim of the present project is to identify predictive biomarkers in malignant melanoma and non-small cell lung cancer that could help to identify patients who are likely to benefit from immunotherapy alone and in combination with other treatments such as radiotherapy.